MERRIMACK PHARMACEUTICALS INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Cash flows from operating activities
Net loss
Income from discontinued operations
Loss from continuing operations
Adjustments to reconcile net loss to net cash used in operating activities
Non-cash interest expense
Amortization and accretion on marketable securities
Loss on extinguishment of debt
Benefit from intra-period tax allocation
Gain on sale of property and equipment
Gain on sale of in progress research and development asset
Gain on sales of in process research and development
Depreciation and amortization expense
Accretion on short-term investments
Stock-based compensation expense
Gain on equity method investment
Changes in operating assets and liabilities:
Prepaid expenses and other assets
Accounts payable, accrued expenses and other
Other assets

Net cash used in operating activities

Cash flows from investing activities
Proceeds from sales and maturities of marketable securities
Proceeds from sale of in progress research and development asset
Proceeds from sale of in-process research and development assets
Proceeds from sale of equity method investment
Proceeds from sale of property and equipment
Proceeds from sale of a discontinued operation
Proceeds from maturity of short-term investments
Purchases of short-term investments
Net cash (used in) provided by investing activities

Cash flows from financing activities
Proceeds from exercise of options
Repayment of debt
Repayment of other liability
Payment of debt extinguishment costs
Payment of dividends

Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Cash paid for interest

Comments